Sir Ian McGeechan: Cancer treatment has worked

Sir Ian McGeechan has given a positive update on his cancer diagnosis, saying 'the treatment has worked'.
The British and Irish Lions legend revealed he had been diagnosed with prostate cancer in an interview with Telegraph Sport last month. The Scot, who was Lions head coach for four tours, said then that he had undergone six weeks of radiotherapy treatment, and would have to wait another six weeks to discover whether it had been successful.
Speaking to fellow Telegraph columnist Will Greenwood during Sky Sports' coverage of the opening Lions game against Argentina, McGeechan revealed he had since received good news about the condition.
Asked about his health, McGeechan answered: 'All good, thank you, the treatment has worked. Fine.' Host Alex Payne added: 'So glad to hear that Geech has had the all clear'.
McGeechan is perhaps the ultimate Lions legend after his unparalleled career both as a player and coach. The 78-year-old was inundated with messages after his Telegraph interview, with the game of rugby uniting to wish him well.
McGeechan has been coaching at Doncaster Knights as he maintains his illustrious career in the game, some 51 years after he first went on a Lions tour as a player in 1974, before being selected again in 1977. McGeechan was then head coach in 1989, 1993, 1997 and 2009, as well as coach of the midweek side in 2005.
When revealing his cancer diagnosis, McGeechan said he hoped his honesty would inspire others to get tested. 'I don't want to make a big thing of it, but it is important to get the message out about urging people to get tested,' he said. 'I said that to our players here. I said to them that they make sure they get themselves tested. If you are younger, it is more important.
'Hopefully this interview can be educational. What I would say to people is don't back off it. It is a blood test, it is not what you always think. Just get it done. I have good people looking after me. It is the very good side of the NHS. The staff of the Bexley Cancer Wing at St James's Hospital in Leeds have been brilliant.
'When I had my last treatment, from the receptionist to the radiographer, they all said: 'Well done, good luck, have a happy time.' Everyone. They all knew. When they are looking up your details and you are going on to your next step, it says which number of treatment is it, and it is what they say to every person when they get to their last treatment, which I think is great. That support and the environment is so positive. What will be, will be.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Independent

17 minutes ago

• The Independent

Weight loss pill shows promise in new trial

A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.

Rhyl Journal

28 minutes ago

• Rhyl Journal

Andy Farrell says Lions ‘won't sugar-coat' defeat to Argentina

The Lions lost their opening tour match for the first time since 1971 after their second-half fightback was overturned when Santiago Cordero finished the match-winning try in the 59th minute. On Saturday they head Down Under before facing the Western Force a week later and Farrell is seeking an immediate response to the error-strewn display seen at a sold-out Aviva Stadium. Not the result we wanted, but a historic night in Dublin. Thank you to the incredible fans who came to see us tonight, and to all of you who tuned in to support us from around the world 🙏🦁#Lions2025 — British & Irish Lions (@lionsofficial) June 20, 2025 'We made it a tough game. Congratulations to Argentina, they thoroughly deserved to win the match. I'm sure that's a big moment in Argentinean rugby history,' Farrell said. 'We had plenty of opportunities and we should have done better to convert them, but the whole story of the game is that we compounded too many errors. 'I wouldn't give familiarity as an excuse. We need to be better than that. The Lions are good players coming together. 'We won't sugar-coat this. We need to be honest because if we're not honest, how do we gain trust with each other? 'Losing hurts, especially in this jersey. We need to find the solutions pretty quickly and be honest with ourselves because some good has to come from this. 'Of course we asked a lot of the players and maybe we put too much pressure on the side because it looked like we were a little disconnected at times. 'We'll review what we said we were going to do as a team. We need to make sure we get something positive from this because it's all about how we move forward. 'Some players will be happy and some players won't and will be dying to get another chance out there. We've got to learn a lot of lessons from that. 'We want to see a better all round performance. There wasn't just one thing, it was the compounding of quite a few bits. 'The amount of balls that we threw blindly either on to the floor or to the opposition was a standout. 'The scraps on the floor always seemed to go to Argentina, so there was a bit more fight and hunger from them that we can't accept.' Maro Itoje criticised the Lions' accuracy as his first outing as captain ended in the tourists' first defeat to Argentina in eight matches.. 'It was a spectacular occasion. The fans gave us a glimpse of what to expect in Australia,' Itoje said. 'We gave ourselves numerous opportunities but we weren't accurate enough at times and weren't consistent enough in piling pressure on to Argentina.'

Daily Mail​

39 minutes ago

• Daily Mail​

Erectile dysfunction drug Viagra has surprise new health benefit, scientists find - offering new hope to 3million ageing Britons

A surprising new health benefit has emerged from the sex drug Viagra - which means three million ageing Britons can now also enjoy a harder skull. The little blue tablet was found to increase the production of vital bone cells, preventing back pain and fractures in old age. Sildenafil - also known as Viagra - can help human stem cells transform into osteoblasts which help the human skeleton regenerate as it is completely replaced roughly once every 10 years. As humans get older, they lose more bone than is built, increasing the risk of breaks or osteoporosis, which makes bones brittle and painful. Follow-up tests on mice by Peking University also suggested a prevention of bone loss. Dr Menglong Hu and Dr Likun Wu told MailOnline: 'Our findings offer new insights into the physiological effects of the medicine. 'Sildenafil enhanced stem cell osteogenic differentiation and inhibited bone loss — it may usefully treat osteoporosis.' Viagra was invented as a heart drug in the 1980s before being found to help with erectile dysfunction. Some studies suggest it may also help reduce the risk of dementia. However, the have been cautions over the years that the drug could have some negative side effects, in particular if taken too much. A large quantity of the drug could result in a painful, 'uncomfortably and disproportionately large erection' called a priapism which could go on for hours. Some experts also found regularly taking the common drug may raise the risk of three serious eye conditions. Common side effects may include headaches, hot flushes, nausea, indigestion, dizziness and a stuffy nose. Nearly half of men between the ages of 40 and 70 suffer from erectile dysfunction in the UK - this is more than 4.5 million people. Though, reports suggest Viagra is now even becoming increasingly popular with younger individuals in their 20s and 30s. Last year, it emerged Viagra may help prevent dementia by boosting blood flow in the brain. 'This is the first trial to show that sildenafil gets into the blood vessels in the brain in people with this condition, improving blood flow and how responsive these blood vessels are,'Dr Alastair Webb, a neurologist and study author at Oxford University said.